Logo image of MDNA

MEDICENNA THERAPEUTICS CORP (MDNA) Stock Fundamental Analysis

NASDAQ:MDNA - Nasdaq - CA58490H1073 - Common Stock - Currency: USD

0.157  -0.02 (-13.16%)

After market: 0.1565 0 (-0.32%)

Fundamental Rating

3

MDNA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MDNA as it has an excellent financial health rating, but there are worries on the profitability. MDNA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MDNA has reported negative net income.
In the past year MDNA has reported a negative cash flow from operations.
In the past 5 years MDNA always reported negative net income.
In the past 5 years MDNA always reported negative operating cash flow.
MDNA Yearly Net Income VS EBIT VS OCF VS FCFMDNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

With a decent Return On Assets value of -27.75%, MDNA is doing good in the industry, outperforming 73.60% of the companies in the same industry.
The Return On Equity of MDNA (-32.55%) is better than 79.04% of its industry peers.
Industry RankSector Rank
ROA -27.75%
ROE -32.55%
ROIC N/A
ROA(3y)-54.92%
ROA(5y)-55.46%
ROE(3y)-62.59%
ROE(5y)-78.09%
ROIC(3y)N/A
ROIC(5y)N/A
MDNA Yearly ROA, ROE, ROICMDNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

MDNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDNA Yearly Profit, Operating, Gross MarginsMDNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, MDNA has more shares outstanding
The number of shares outstanding for MDNA has been increased compared to 5 years ago.
There is no outstanding debt for MDNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MDNA Yearly Shares OutstandingMDNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
MDNA Yearly Total Debt VS Total AssetsMDNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -2.42, we must say that MDNA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MDNA (-2.42) is comparable to the rest of the industry.
There is no outstanding debt for MDNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.42
ROIC/WACCN/A
WACCN/A
MDNA Yearly LT Debt VS Equity VS FCFMDNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M

2.3 Liquidity

A Current Ratio of 9.74 indicates that MDNA has no problem at all paying its short term obligations.
With a decent Current ratio value of 9.74, MDNA is doing good in the industry, outperforming 72.44% of the companies in the same industry.
MDNA has a Quick Ratio of 9.74. This indicates that MDNA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.74, MDNA is in the better half of the industry, outperforming 72.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.74
Quick Ratio 9.74
MDNA Yearly Current Assets VS Current LiabilitesMDNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

MDNA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 56.76%, which is quite impressive.
EPS 1Y (TTM)56.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 51.29% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-26.16%
EPS Next 2Y-24.06%
EPS Next 3Y-17.48%
EPS Next 5Y51.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDNA Yearly Revenue VS EstimatesMDNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M
MDNA Yearly EPS VS EstimatesMDNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDNA. In the last year negative earnings were reported.
Also next year MDNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDNA Price Earnings VS Forward Price EarningsMDNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDNA Per share dataMDNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

MDNA's earnings are expected to decrease with -17.48% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-24.06%
EPS Next 3Y-17.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDICENNA THERAPEUTICS CORP

NASDAQ:MDNA (11/1/2023, 8:00:01 PM)

After market: 0.1565 0 (-0.32%)

0.157

-0.02 (-13.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-28 2023-07-28/bmo
Earnings (Next)11-09 2023-11-09/bmo
Inst Owners0.18%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap10.93M
Analysts83.64
Price Target2.88 (1734.39%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.91%
Min EPS beat(2)29.41%
Max EPS beat(2)36.41%
EPS beat(4)4
Avg EPS beat(4)46.58%
Min EPS beat(4)29.41%
Max EPS beat(4)78.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-26.64%
PT rev (3m)-18.64%
EPS NQ rev (1m)1%
EPS NQ rev (3m)5.71%
EPS NY rev (1m)0%
EPS NY rev (3m)3.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-16.67%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-0.12
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.14
FCFYN/A
OCF(TTM)-0.14
OCFYN/A
SpS0
BVpS0.28
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.75%
ROE -32.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.92%
ROA(5y)-55.46%
ROE(3y)-62.59%
ROE(5y)-78.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.74
Quick Ratio 9.74
Altman-Z -2.42
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)56.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y-26.16%
EPS Next 2Y-24.06%
EPS Next 3Y-17.48%
EPS Next 5Y51.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y20.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.59%
OCF growth 3YN/A
OCF growth 5YN/A